FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma By Ogkologos - January 28, 2026 321 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRANSCEND FL-MZL Cohort Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Median Survival Times for Two Forms of Advanced Breast Cancer Have... November 9, 2021 Darolutamide Extends Survival for Some People with Metastatic Prostate Cancer March 25, 2022 Encorafenib, Cetuximab Combination Approved for Metastatic Colorectal Cancer May 8, 2020 Cancer Surgery Unexpectedly Canceled for Mother of Two, Who Says It’s... March 31, 2020 Load more HOT NEWS NCI’s Rare Cancer Clinics: Engaging Patients and Fostering Collaboration Boy Asks Mom Fighting Cancer To Take Off Her Turban So... Five Questions With…Desiree. EMA Recommends Extension of Indications for Inotuzumab Ozogamicin
